Earlier ofatumumab treatment May reduce disease progression and relapses for patients with relapsing-remitting multiple sclerosis: results from a cost-consequence model

被引：0

作者：

Green, L. ^{[1
]}

Montgomery, S. ^{[1
]}

Durand, A. ^{[2
]}

Loh, J. ^{[2
]}

机构：

[1] Costello Med, Cambridge, England

[2] Novartis Pharmaceut UK Ltd, London, England

来源：

MULTIPLE SCLEROSIS JOURNAL | 2022年 / 28卷 / 3_SUPPL期

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

EP1105

引用

页码：875 / 875

页数：1

共 3 条

[1] Ofatumumab versus Teriflunomide in Multiple Sclerosis [J].

Hauser, Stephen L. ;

Bar-Or, Amit ;

Cohen, Jeffrey A. ;

Comi, Giancarlo ;

Correale, Jorge ;

Coyle, Patricia K. ;

Cross, Anne H. ;

de Seze, Jerome ;

Leppert, David ;

Montalban, Xavier ;

Selmaj, Krzysztof ;

Wiendl, Heinz ;

Kerloeguen, Cecile ;

Willi, Roman ;

Li, Bingbing ;

Kakarieka, Algirdas ;

Tomic, Davorka ;

Goodyear, Alexandra ;

Pingili, Ratnakar ;

Haring, Dieter A. ;

Ramanathan, Krishnan ;

Merschhemke, Martin ;

Kappos, Ludwig .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (06) :546-557

[2] Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis [J].

Samjoo, Imtiaz A. ;

Worthington, Evelyn ;

Drudge, Christopher ;

Zhao, Melody ;

Cameron, Chris ;

Haering, Dieter A. ;

Stoneman, Dee ;

Klotz, Luisa ;

Adlard, Nicholas .

JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2020, 9 (18) :1255-1274

[3]

Scolding Neil, 2015, Pract Neurol, V15, P273, DOI 10.1136/practneurol-2015-001139

← 1 →